Many patients with stage I nonsmall cell lung carcinoma will develop recurrence after surgical excision. Sox2 is a marker of embryonic stem cell pluripotency that is associated with aggressive tumor behavior and is expressed in a subset of lung adenocarcinomas. We hypothesized that Sox2 expression may provide prognostic information in early stage lung adenocarcinomas. We evaluated formalin-fixed, paraffinembedded tissue from 104 stage I lung adenocarcinomas resected between 1997 and 2000. Sox2 expression was analyzed by immunohistochemistry and compared with clinicopathologic features, time-to-progression, and overall survival (OS). Sox2 expression was detected in 50% of the cases and was more frequent in tumors from older and male patients but not significantly associated with smoking status, tumor stage, grade, or histologic subtype. Compared with Sox2-negative tumors, Sox2 expression predicted a shorter time-to-progression (49% vs. 82% at 5 y; P = 0.0006) and shorter OS (54% vs. 79% at 5 y; P = 0.004). By multivariate analysis, Sox2 expression predicted a greater risk of progression among men [hazard ratio (HR) 5.6; 95% confidence interval (CI) 2.3-13.8] and women (HR 2.1; 95% CI 0.8-5.7). Sox2 expression was associated with significantly shorter OS among men (HR 2.5; 95% CI 1.2-5.1), but not in women. Sox2 seems to be an independent predictor of poor outcome in stage I lung adenocarcinomas and may help stratify patients at increased risk for recurrence. FIGURE 2. Time-to-progression in patients with lung adenocarcinoma based on Sox2 expression and sex.
L ung cancer is among the most common and morbid cancers in the United States. 15, 16 The majority of lung cancers are nonsmall cell carcinomas (NSCLC), the most common types of which are adenocarcinoma (ACA) and squamous cell carcinoma (SCC). Although SCC has been decreasing in incidence with changes in smoking patterns, ACA is increasing in incidence, particularly among women. 25 NSCLC mortality is predicted in large part by tumor stage, with a median survival of more than 8 years for stage I and <1 year for stage IV patients. 9 Although surgery can be curative for early stage disease, 6 a significant subset of these patients develop metastases.
Several groups have attempted to identify markers of more aggressive tumor behavior using gene expression profiling 7, 11, [20] [21] [22] ; however, this approach is hampered by the lack of overlap between gene signatures identified by individual groups, a problem thought to be related to tumor heterogeneity and varying statistical approaches. 5 Immunohistochemistry (IHC) is a potentially more cost effective and faster way to identify tumor signatures via their protein expression profiles. 29, 30 However, to date there is no single IHC marker that is used routinely for prognostic purposes in early stage NSCLC.
Sox2 is a transcription factor that is involved in the maintenance of embryonic stem cell pluripotency 14, 27 and in multiple developmental processes, including lung branching morphogenesis. 13 In tumor gene expression studies, analyses of genes known to be active in development and differentiation have shown that Sox2 is overexpressed in certain poorly differentiated subtypes of cancer. 3, 8 A cancer therapy outcome predictor algorithm that incorporates genomic analysis of ''stemness'' pathways, including the Nanog/Oct4/Sox2 pathway, demonstrates high prognostic accuracy in retrospective studies of patients with multiple tumor types, including lung cancer. 10 Expression of Sox2 protein has not been extensively studied in lung cancer; however, we have recently demonstrated that Sox2 is strongly and diffusely expressed in B90% of pulmonary SCC and B20% of ACA. 23 Given the association between Nanog/Oct4/Sox2 pathway gene expression and aggressive tumor types, and given the fact that Sox2 is expressed in a subset of ACA, we hypothesized that Sox2 may be associated with poor prognosis in lung ACA. The purpose of this retrospective study was to evaluate the prognostic value of Sox2 expression in surgically resected stage I lung ACA.
MATERIALS AND METHODS

Study Population
We collected 151 consecutive cases of surgically resected stage I lung ACA (T1 N0 M0 or T2 N0 M0) in the period ranging from 1997 to 2000 from the pathology files of Brigham and Women's Hospital, after approval by the Partners Institutional Review Board (Partners Institutional Review Board numbers 2009P001426 and 2006P001921). Diagnoses were confirmed, tumors were graded and subtyped according to World Health Organization criteria, 26 and staged according to the American Joint Committee on Cancer criteria by 3 pathologists (L.M.S., J.A.B., and L.R.C.). 9 On review, 5 tumors were reclassified as adenosquamous or large cell neuroendocrine carcinomas and were excluded from further analysis.
Patient demographic and outcome data were retrieved from the electronic medical records; 24 patients were lost to follow up and were excluded. Four patients with concurrent cancer diagnoses (not including skin squamous cell and basal cell carcinomas) were excluded. Of the remaining patients, 14 had insufficient tissue for IHC studies, leaving 104 cases for the final analysis.
IHC
Sox2 expression was evaluated on 37 ACA included in a tissue microarray (TMA) that was previously described 1 and 67 ACA using whole tissue sections. Briefly, a TMA of formalin-fixed, paraffin-embedded tumor containing three 0.6 mm cores from each sample was constructed. The areas included on the TMA were carefully selected to ensure that heterogeneous tumors were well represented. IHC for Sox2 (rabbit polyclonal antibody; 1:500 dilution; Novus Biologicals, Littleton, CO), thyroid transcription factor-1 (TTF-1) (Clone 8G7G3/1; 1:1000 dilution; Dako, Carpinteria, CA), Nanog (goat polyclonal; 1:500 dilution; R&D Systems, Minneapolis, MN), and Oct3/4 (rabbit polyclonal; 1:150 dilution; Santa Cruz Biotechnology, Santa Cruz, CA) were performed after heat-induced epitope retrieval in citrate buffer (pH 6) using a pressure cooker.
Nuclear staining was considered positive. We graded the immunoreactivity by 2 methodologies: (1) semiquantitatively with 0 as no staining; 1+, <5% tumor cells staining; 2+, 5% to 25% tumor cells staining; 3+, 26% to 50% tumor cells staining; and 4+, greater than 50% tumor cells staining and (2) as negative or positive using a 5% cutoff.
Statistical Analysis
Comparison of clinicopathologic characteristics and Sox2 expression was performed using the Wilcoxon rank-sum and Fisher exact tests. The median potential follow-up time using censored data was 96 months. Timeto-progression (TTP) was computed from time of surgery to time of clinical diagnosis of recurrent carcinoma; patients who died without documentation of recurrence were censored. Overall survival (OS) was calculated from time of surgery to time of death from any cause or to time of last follow-up, at which point the data were censored.
The logrank (Mantel-Cox) test and Kaplan-Meier estimation were used to examine the TTP and OS. The Cox proportional hazards model was used to perform regression analysis of the failure time data. In addition to controlling for stage, which is prognostic for NSCLC, the multivariate analysis was adjusted for the clinicopathologic characteristics that were associated with Sox2 expression. All reported P values are based on a 2-sided hypothesis. The data analysis was conducted primarily using GraphPad Prism 5 (GraphPad Software, Inc, La Jolla, CA) and SAS 9.1 (SAS Institute Inc, Cary, NC).
RESULTS
Patient Demographics and Pathologic Characteristics
Patient demographic and surgical and tumor pathologic data are detailed in Table 1 . There were relatively more women in the study. The majority of patients were smokers. Fifty percent of patients were stage IA and 50% of patients were stage IB. Eighty-two percent of cases had mixed subtype histology. Acinar pattern was most commonly the predominant subtype (51%), followed by papillary (18%), solid (17%), and bronchioloalveolar (13%). Of the 19 cases that contained a single histologic subtype, 7 (37%) were acinar, 5 (26%) were papillary, and 7 (37%) were solid. None of the cases were pure bronchioloalveolar carcinomas. 
Sox2 Expression in Lung ACA
Using the semiquantitative scoring system, 36 (35%) cases had no Sox2 staining (0), 16 (15%) cases had <5% tumor cells staining (1+), 14 (13%) cases had 5% to 25% tumor cells staining (2+), 20 (19%) cases had 26% to 50% tumor cells staining (3+), and 18 (17%) had greater than 50% tumor cells staining (4+). This is consistent with previously reported data. 23 Using the 5% cutoff, Sox2 expression was observed in 17 of 37 (46%) cases evaluated by TMA and in 35 of 67 (52%) cases evaluated as whole tissue sections (P = 0.68). Overall, 52 (50%) cases were considered positive using this cutoff (see below). Representative images of Sox2 expression in low and high-grade tumors are shown in Figure 1 .
TTF-1 was positive in 92 (88%) cases. Oct3/4 and Nanog protein expression was very weak and was detected in only rare cells in 8% and 7% of cases, respectively. Based on a 5% cutoff, both markers were considered negative in all cases.
Patient clinical characteristics were correlated with Sox2 expression ( Table 2) . Median age was higher in patients with Sox2-positive tumors (69 y vs. 64 y, P = 0.05). Patients older than 60 years of age were more likely than those less than 60 years of age to have Sox2-positive tumors (58% vs. 35%, P = 0.04). Sox2-positive tumors were more frequent in men (61%) than in women (44%); however, this difference was not statistically significant (P = 0.15). There was no significant difference in Sox2 expression based on smoking status or resection type.
Tumor pathologic characteristics were correlated with Sox2 expression (Table 3 ). There was no difference in the average size of Sox2-negative and Sox2-positive tumors (2.4 cm vs. 2.5 cm). Tumors with pleural invasion were more likely to show Sox2 expression than those without pleural invasion (61% vs. 44%); however, this difference was not statistically significant (P = 0.14). There was no significant difference in Sox2 expression based on tumor stage, grade, or dominant histologic subtype. Of note, both ACAs in our study that had prominent mucinous features were strongly Sox2 positive.
One Sox2-negative and 2 Sox2-positive tumors had positive surgical margins, none of which received adjuvant therapy. Margins could not be assessed in 2 cases. Three patients with Sox2-negative tumors and 3 patients with Sox2-positive tumors received adjuvant therapy (4 patients received local radiotherapy only, 1 patient with a Sox2negative tumor received both radiotherapy and chemotherapy, and 1 patient with a Sox2-positive tumor received chemotherapy only).
Survival Analysis
Univariate survival analysis was performed for each cutoff in the semiquantitative Sox2 scoring system; greater than 5% tumor cell staining proved to be the strongest predictor of survival (data not shown), and this cutoff was therefore used for the analyses.
By univariate analysis, Sox2 expression predicted a shorter TTP (P = 0.0006). At 5 years, 82% of the patients with Sox2-negative ACA and 49% of patients with Sox2-positive ACA were disease free. Exploring the interaction between Sox2 expression and patient sex, men and women with Sox2-negative tumors had virtually identical TTP curves (P = 0.59). Although Sox2-positive ACA are associated with shorter TTP among both sexes (Fig. 2) , men with Sox2-positive tumors had significantly shorter TTP than did women (P = 0.03). Accounting for the sex differences as well as controlling for age and stage, the risk of progression was more than 5 times higher [hazard ratio (HR) 5.6; 95% confidence interval (CI) 2.3-13.8] among male patients with Sox2-positive tumors (P = 0.0002). In contrast, women with Sox2-positive tumors were twice as likely to progress (HR 2.1; 95% CI 0.8-5.7) compared with all those with Sox2-negative tumors but this difference was not statistically significant (P = 0.12).
By univariate analysis, Sox2 expression was also a significant predictor of a shorter OS (P = 0.004). The OS at 5 years was 79% in the Sox2-negative group and 54% in the Sox2-positive tumors (Fig. 3 ). After allowing for differential sex effects as well as adjusting for age and stage, Sox2 expression is associated with more than double the risk of dying (HR 2.5; 95% CI 1.2-5.1) among male patients compared with all those with Sox2-negative tumors (P = 0.01). In contrast, the risk of death is increased moderately (HR 1.6; 95% CI 0.8-3.2) for female patients, but this difference was not statistically significant (P = 0.2).
Of the 52 patients with Sox2-positive tumors, 23 (44%) had clinically documented progression: 11 patients developed metastatic disease and 12 patients had a local recurrence. During the same period, of the 52 patients with Sox2-negative tumors, 8 (15%) had progression: 5 patients developed metastatic disease and 3 had a local recurrence.
DISCUSSION
There is a pressing need for additional markers to provide prognostic information in early stage lung cancer, as the current surgical-pathologic staging system cannot predict which stage I lung cancers will be cured by surgery alone and which will recur. Patients with more aggressive tumors may benefit from adjuvant therapy, if they can be identified at the time of surgical resection. A significant effort has been made to identify markers that can provide this prognostic information in the form of gene expression and IHC analysis. Most of the currently available models for prognostication in early stage lung cancer are not in widespread use, and, in the case of gene expression analysis, are prohibitively expensive. In Sox2, we have identified a single IHC marker that is easily interpreted, inexpensive, and highly associated with shorter TTP and OS in stage I lung ACAs.
We examined expression of the transcription factors Nanog, Oct3/4, and Sox2 in surgically resected lung ACAs. Prior studies have demonstrated increased gene expression of Nanog, Oct3/4, and Sox2 and their downstream targets in aggressive tumor types. 3, 10 Of note, in our study only Sox2 showed significant protein expression in tumor cells. This discrepancy may be a function of the different methodologies employed, but also raises the possibility that Sox2 is acting independently of its usual cofactors in lung cancer, or alternatively that the sensitivity of the available antibodies when used for IHC may be too low to detect the levels of Nanog and Oct3/4 expressed in this tumor type.
We correlated Sox2 expression with patient characteristics, tumor pathology, and survival. Other than a higher frequency observed with older patient age and male sex, Sox2 expression was not significantly associated with any other clinical or pathologic variables, including histologic subtype, grade, T classification, or TTF-1 expression. Although not statistically significant, it is interesting to note that Sox2 expression was more commonly associated with pleural invasion. Preliminary studies of Sox2 in melanoma have suggested that Sox2 expression may be associated with local tumor progression. 19 Sox2 was strongly prognostic, even after adjusting for other clinical variables including age and sex. Sox2 expression was significantly associated with shorter TTP and OS by univariate and multivariate analyses. Of note, men with Sox2-expressing tumors were more likely to progress than were women; their risk of death was about double compared with all those with Sox2negative tumors.
Possible pitfalls include use of this marker in large cell neuroendocrine carcinomas or SCCs that may have been misdiagnosed as ACAs; because B80% of large cell neuroendocrine carcinoma and greater than 90% of pulmonary SCCs show Sox2 expression, 23 it is unlikely that this marker would have prognostic value in these cases. The utility of this marker in tumors of mixed adenosquamous histology has not been examined.
The biologic significance of Sox2 overexpression in lung ACA is not yet known. The lack of correlation between Sox2 and TTF-1 expression in these tumors suggests that its expression is not related to tumor differentiation pathways. Of note, SOX2 has been identified as an oncogene that undergoes amplification in lung and esophageal SCCs. 2 Large scale copy number gains have been reproducibly detected in several regions of the NSCLC genome, including at 3q, 5p, and 8q. 12, 28 Sox2 is located at 3q26. Comparative genomic hybridization studies have demonstrated that greater than 90% of SCCs and B20% of ACAs have copy number gain involving 3q26, 4 essentially the same proportions that have been demonstrated to have high level Sox2 expression at the protein level. 23 Of note, these studies have found high level amplification only in SCC. 4 Epigenetic regulation of Sox2 has been shown to drive its expression in neural systems, with effects on cell proliferation and differentiation. 24 These observations warrant additional studies to determine the molecular mechanisms of Sox2 expression in ACA. Correlation between Sox2 expression and the mutation status of established predictive markers such as epidermal growth factor receptor and KRAS will be of particular interest.
To date there is no single IHC marker that is used routinely for prognostic purposes in early stage NSCLC. A recent report has identified a combination of clinical parameters and IHC marker panels that provide independent prognostic information in stage IB NSCLC 30 ; however, the proposed algorithms are relatively complex and time consuming. Sox2 is currently used in clinical practice to aid in identification and subtyping of germ cell tumors, but it has limited known application outside of that context. It now appears that it can effectively identify those early stage lung ACAs that are more likely to recur in the first 5 years after surgery. The findings in this retrospective study require prospective validation. In this study, the strength of the association between Sox2 expression and poor outcomes is on par with that of other established poor prognostic markers, including lymphovascular invasion, solid histology, and tumor size. 17, 18 However, Sox2 expression seems to be independent of these and other pathologic features, suggesting that it may serve as a novel prognostic marker, enabling the identification of those high-risk patients who may benefit from adjuvant therapy.
